Purpose: Serous ovarian carcinomas are the predominant epithelial ovarian cancer subtype and it has been widely believed that some or all of these may arise from precursors derived from the ovarian surface epithelium or fimbriae, although direct molecular evidence for this is limited. This study aimed to conduct copy number (CN) analysis using a series of benign and borderline serous ovarian tumors to identify underlying genomic changes that may be indicative of early events in tumorigenesis.
Introduction
Ovarian cancer is a very significant health burden and the 7th leading cause of cancer death in women worldwide (1) .
At the time of diagnosis, women with epithelial ovarian cancer usually have advanced disease and as a consequence their prognosis is extremely poor (5-year survival rate for stage III and IV disease is only 25%-30%; refs. 2, 3). For such a clinically significant disease, remarkably little is known about the molecular events that initiate the disease. Although the paradigm that malignancies arise through a stepwise progression from benign precursors has been established for many malignancies, the archetypical example being colorectal carcinogenesis (4) , it remains unclear if this holds true for ovarian cancer. There is still considerable controversy as to what constitutes a true ovarian cancer precursor; an important definition that needs to be made to understand the origins and identify new clinical interventions for this lethal disease.
Serous ovarian carcinomas are the predominant clinically important subtype but at present there is little experimental evidence from which to draw convincing conclusions about what constitutes the precursor(s) to this subtype. It has been widely believed that some or all of these arise from precursors originating from the ovarian surface epithelium, via inclusion cysts or serous benign and borderline tumors (5) (6) (7) (8) . Obvious candidate precursors are serous ovarian cystadenomas and cystadenofibromas, which are benign lesions with a cystic mass of 1 cm or more in diameter, lined with a single layer of cuboidal to columnar epithelium and commonly associated with a fibromatous stromal mass ( Supplementary Fig. S1 ). The serous epithelial layer of these tumors typically displays minimal cellular proliferation and no nuclear atypia. These are relatively common tumors, accounting for 60% of all serous ovarian tumors, whereas serous borderline tumors (SBT) and low-grade serous carcinomas (LGSC) account for 10%-15% and 2%-9% of all serous ovarian tumors, respectively (9) (10) (11) (12) . Benign serous tumors are presumed by many to be precursors to SBTs based on similarities in the cystic structure of some SBTs and the frequent detection of cases with a benign cyst coexisting with a SBT or cases comprising predominantly benign cysts with regions of atypical proliferation (13) . Despite the cooccurrence of benign, borderline, and low-grade carcinoma epithelial components, direct molecular evidence supporting benign lesions as precursors is limited. Although some studies have shown the existence of KRAS and BRAF mutations in ovarian serous cystadenomas and cystadenofibromas co-existing with a region of atypical proliferation or adjacent SBT (14) , mutations in these genes have not been detectable in solitary benign tumors.
SBTs have been firmly established as the likely precursor lesions to LGSCs, sharing similar rates of KRAS and BRAF mutation and low levels of genomic instability (15) (16) (17) (18) . This is in contrast to the high rates of TP53 mutation and high levels of genomic alteration observed in high-grade serous carcinomas (18, 19) . Traditionally, these have been believed to arise from ovarian surface epithelium and epithelial inclusion cysts formed from invaginated surface epithelium (5). More recently, circumstantial evidence has been published suggesting that serous ovarian carcinomas may not arise from the ovary at all and may in fact originate from fallopian tube epithelium (20, 21, 22, 23) .
With the aim of identifying somatic genomic changes that may be indicative of early events in tumorigenesis and which could assist in determining if these represent precursors to some invasive serous ovarian carcinomas, we have conducted high-resolution CN analysis on a series of benign and borderline serous ovarian tumors. This is the first ultra-high-resolution CN analysis of benign serous tumors of the ovary.
Materials and Methods

Tissue samples
Only fresh frozen tissue samples were used in this for CN and mutation analyses. All samples were collected with the informed consent of patients and the study was approved by the Human Research Ethics Committees at the Peter MacCallum Cancer Centre, Queensland Institute of Medical Research, University of Melbourne and all participating hospitals. Patients with ovarian tumors were identified through 2 primary sources: (i) 9 at hospitals in Southampton (24) , United Kingdom, (ii) 54 through the Australian Ovarian Cancer Study (25) . Pathology reviews were done independently by 2 gynecologic pathologists (R. Sharma and C.B. Gilks). Pathology review was conducted on cryosections adjacent to the tissue from which DNA was extracted (n ¼ 63).
Microdissection and DNA extraction
A representative hematoxylin and eosin (H&E) stained section was assessed and needle microdissection was done using 10 mm sections to obtain high percentage tumor epithelial cell and fibroblast cell components. DNA was extracted using the Qiagen Blood and Tissue Kit (Qiagen). Normal DNA extracted from blood lymphocytes was available for all 63 patients.
CN arrays
A subset of cases were processed by Affymetrix for the OncoScan (Molecular Inversion Probe) assay, which consists of a 330K probe set that allows the detection of genome-wide, allele-specific CN. OncoScan data normalization was done by Affymetrix Inc. as previously described (26, 27) . Where sufficient material ( 250 ng DNA) was available, the Affymetrix SNP6.0 (1.8M probe set) arrays were utilized for ultra-high-resolution allelespecific CN analysis, although prior to its release the Affymetrix 500K array was used. For the SNP6.0 array the input was reduced from the recommended 500 to 250 ng with no detectable difference in the quality of the data. Reaction volumes were halved accordingly prior to the SNP6.0 PCR step. MAPD scores (pass 0.4) for samples run on OnsoScan and SNP6 platforms are available in Supplementary Tables S5 and S6 .
Data analysis
The SNP and OncoScan data were analyzed using Partek Genomics Suite 6.5, using paired and unpaired CN generation, allele-specific CN analysis and circular binary segmentation (CBS) to identify regions of CN aberration and LOH. Regions of CN aberration and LOH were confirmed through examination of allele-specific CN ratios.
Translational Relevance
Ovarian cancer is a very significant health burden and the seventh leading cause of cancer death in women. At the time of diagnosis, women often have advanced disease and as a consequence their prognosis is extremely poor. Our understanding of the progression of ovarian cancer through precursor stages and the molecular genetic events underlying these changes is very limited. Although a number of candidate precursor lesions have been proposed, the true contribution of these precursor lesions to the onset of ovarian cancer is unresolved. Identifying genuine ovarian cancer precursors and defining key molecular genetic events initiating and promoting tumorigenesis have important implications in early detection and treatment of ovarian cancers.
Mutation screening
DNA sequencing was done by Sanger sequencing using BDT v3.1 reagents (Applied Biosystems) and an ABI3130 sequencer. Sequencing was used to identify the most common serous ovarian tumor mutations: BRAF codon 600, KRAS codons 12 and 13, TP53 exons 5-8 and ERBB2 exon 20 ( Supplementary Fig. S3 ). Primer sequences are detailed in Supplementary Table S1 and specific mutations identified are detailed in Supplementary Table S2 .
FISH and aneusomy
FISH was carried out on 6 mm formalin-fixed, paraffinembedded (FFPE) sections using the following commercial and in-house BAC probes: Cep12 (orange, 12p11. Fibrous stroma noted on review. c Fibrous stroma not noted on review.
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Molecular; #32-801300). Aneusomy analysis was conducted on 6 mm FFPE sections using a commercial assay from Abbott Molecular (formerly Vysis), Breast Cancer Aneusomy Multi-Color Probe Kit: Vysis LSI 1 -1p12 Spectrum Gold (yellow), Vysis CEP 8 -8p11.1 Alpha Satellite DNA Spectrum Red, Vysis CEP 11 -11p11.11-q11 Spectrum Green, and Vysis CEP 17 -17p11.1-q11.1 Spectrum Aqua. All hybridizations were carried out as previously described (28) . Imaging was done on a Zeiss Axioplan epifluorescent microscope.
Results
Benign serous tumor CN analysis H&E-stained sections from a cohort of benign serous tumors (serous cystadenomas and cystadenofibromas) were reviewed to identify cases where sufficient epithelial and stromal tissue could be microdissected to conduct highresolution, genome-wide, allele-specific CN analysis. A total of 14 serous cystadenomas and 21 serous cystadenofibromas were identified where CN could be analyzed in matching epithelium, fibroblasts, and germ line (lymphocyte) DNA.
All tissues were microdisssected to achieve more than 80% pure epithelial or fibroblast cell populations (Supplementary Fig. S2 ), which we have shown previously is sufficient purity to reliably identify CN aberrations and LOH (29) . CN aberrations and/or LOH were detected in the epithelial component in one of the 35 cases (2.9%) but surprisingly, 12 of the 35 cases (34.3%) harbored CN aberrations and/or LOH in the fibroblast component (Table 1 ). In one of these cases unique CN changes were detected in both the epithelium and fibroblasts, consistent with this case comprising 2 distinct and independent tumors (Fig. 1) . Overall, fibroblast components from 14.3% of the serous cystadenomas and 47.6% of the cystadenofibromas harbored CN/LOH alterations (Supplementary Table S3 ). Among the 12 cases with CN/LOH changes, 9 (75%) showed gain of chromosome 12 and 3 (25%) showed LOH of chromosome 22.
In a further attempt to identify evidence of somatic genetic events in the epithelial component, each sample was analyzed for mutations in KRAS codons 12 and 13, BRAF codon 600, TP53 exons 5-8 and ERBB2 exon 20 but no mutations were detected in the either the fibroblast or epithelial component of any case.
The observed rate of CN/LOH alterations in the fibroblasts was nearly 3 times greater in cystadenofibromas compared with cystadenomas. However, as these cases were selected on the basis of the presence of microdissectible epithelium we considered that it was possible they may not have been representative of the typical spectrum of benign serous tumors. Therefore, the fibroblast component from 10 consecutive benign serous tumors [5 cystadenomas and 5 cystadenofibromas; 6 of these are also reported in (Table 1) ] were analyzed for CN/LOH alterations using SNP6.0 arrays (Supplementary Table S4 ). The frequency of CN/LOH alterations present in the fibroblasts from these cystadenofibromas was similar to the original set of selected cases (40.0% vs. 42.9%) but was much higher among the cystadenomas (40% vs. 14.3%) although this was not statistically significant (P ¼ 0.2722, the Fisher exact test). All 4 cases with CN/LOH alterations included gain of chromosome 12. Among the entire cohort, 13 of 39 cases (33.3%) showed CN/LOH alterations in the fibroblast component.
SBT CN analysis
Given that many of the benign serous tumors seemed to be neoplastic fibromatous masses rather than genuine epithelial tumors it was plausible that a similar situation might also exist for SBTs. Consequently we conducted high-resolution, genome-wide CN analysis on epithelial and fibroblast components from a series of SBTs. Among the 24 SBTs analyzed, CN/LOH aberrations were detected in 16 of 24 epithelial components (67%) and in 3 of 20 fibroblast components (15%; detected in the epithelial component in 57.9% of cases (Table 2) ; however, no TP53 or ERRB2 mutations were detected. Overall, CN/LOH and/or BRAF/KRAS mutations were detected in the epithelial component of all but one of the borderline tumors. In all 3 cases where CN aberrations were detected in the fibroblasts component, unique CN aberrations were also detected in the adjacent epithelial component showing they were not clonal variants of a common initiating tumor ( Table 2 , Supplementary Fig. S4 ).
FISH
As noted above, gain of chromosome 12 was the most common CN aberration among stromal components of benign tumors. To confirm the presence of the chromosome 12 gain in the fibroblasts from the benign serous tumors and to determine absolute CN, FISH was carried out on 2 cases where suitable tissue was available (cases A2 and A6). Both A2 and A6 were confirmed to have trisomy of chromosome 12 in the majority of fibroblasts. Interestingly, A2 seemed to have 4 copies of chromosomes 12 and 15 (a chromosome 15 probe was used as a control) in some of the epithelial cells (Fig. 2) . Balanced tetrasomy in clusters of epithelial cells was confirmed using an aneusomy detection kit and centromeric probes for chromosomes 1, 8, 11, and 17 ( Supplementary Fig. S5 ). Completely balanced tetrasomy is not readily detectable by SNP array as CN is calculated after a median-centered normalization procedure. Further examination of the SNP allelic ratio was also unable to detect imbalance, suggesting either this duplication is nearly perfectly balanced or an insufficient proportion of affected cells were present to make the distinction. FISH was also carried out on a tumor microarray with tissues from normal ovary (6), benign cordstromal tumors (3), benign endometriosis (4), and SBTs (42) . Only a single SBT was identified with chromosome 12 trisomy in approximately 45% of fibroblast cells, although this case also had features of low-grade serous carcinoma/psammocarcinoma.
Discussion
This study has shown that CN/LOH aberrations in the epithelium of benign serous tumors are rare, occurring in just one (2.9%) of cases studied, whereas aberrations in the fibromatous components were more frequent, occurring in 33.3% of cases. Where CN/LOH aberrations were observed in the epithelial components these were similar to those identified in previous studies of benign serous tumors (Table 3 ; ref. 30, 31) . Although the rate of epithelial CN/ LOH events in this study is significantly lower than previously reported, artifactual LOH events may have been introduced when conducting microsatellite analyses on low quantities of DNA in these previous studies (32) . Our findings are consistent with the findings of Cheng and colleagues (33) who showed in a cohort of 29 ovarian serous cystadenomas that only 14% of these tumors had detectable monoclonal expansion in the epithelium.
The absence of detectable KRAS, BRAF, ERBB2, or TP53 mutations in the epithelial component of any benign serous lesion in this study is consistent with the low rate of such mutations reported from previous studies (17, 31) . Reports of KRAS and BRAF mutations in ovarian serous cystadenomas and cystadenofibromas have been limited to a small number of cases with a coexisting region of atypical proliferation or adjacent SBT (14) . Despite the small number of CN/LOH aberrations present in the epithelium of benign serous tumors, combining our data with published studies shows that they have similar profiles to a proportion of SBTs, such as gain of 6p and 7q. If the benign serous tumors with CN/LOH aberrations are indeed precursors to SBT, the absence of either KRAS or BRAF mutations, characteristic of SBTs, might indicate that acquisition of these mutations accompanies progression to a SBT. This possibility is consistent with the observations of Singer and colleagues (ref. 6) who showed that bilateral SBTs frequently shared a subset of CN aberrations but rarely shared identical KRAS mutations, indicating that the CN aberrations are likely occurring earlier than the acquisition of KRAS mutations and precede dissemination to the contralateral ovary. CN aberrations as early events in ovarian serous neoplasia is further supported by studies that have identified aneuploidy, but not mutations, in ovarian inclusion cysts and even at low levels in ovarian surface epithelium (7, 8) . Alternatively, the absence of identifiable KRAS or BRAF mutations in benign serous tumors with clear clonal expansion events leaves open the possibility that they may be precursors for other serous ovarian cancers. The tetrasomy identified in the epithelial component in case A2, adjacent to fibroblasts with chromosome 12 trisomy, is a particularly intriguing finding in light of ploidy studies by Pradhan and colleagues that identified tetraploidy in 7 of 40 high-grade serous carcinomas, 0 of 22 LGSCs, and 0 of 245 SBTs (34) .
In contrast to the benign serous tumors, CN/LOH events were identified in the epithelial component in 16 of 24 (67%) of SBTs; similar aberrations have been detected in previous studies (Table 3) . Although limited CN/LOH data is available that distinguishes low-grade serous from high grade serous and other histologic types of ovarian cancer, overlapping CN/LOH events support the model of SBTs as precursors to LGSCs (Table 3) . Among the borderline tumors 57.9% harbored KRAS or BRAF mutations, consistent with previous reports for both SBTs and LGSCs (18, 35) .
An important finding of this study is that the fibromatous components of benign tumors frequently harbor identifiable clonal CN/LOH alterations, strongly suggesting that many tumors originally classified as benign epithelial tumors are in fact primary fibroblastic tumors with an associated epithelial cyst. This supports the work of Seidman and Mehrota (ref. 36) , who published a review of 113 unselected benign serous ovarian tumors to assess the rate of epithelial "neoplasia" based on the presence of a minimum of 1 mm (2) area of epithelial proliferation, finding that only 7% of cases passed this criterion. Seidman and Mehrotra predicted that 81% of serous cystadenofibromas are in reality fibromas with epithelial inclusions and that 99% of serous cystadenomas are cystically dilated glandular inclusions. Consequently, they concluded that the majority of these tumors should not be considered serous neoplasms. Consistent with finding of the study of Seidman and Mehrota of greater evidence of "true" neoplasia in cystadenofibromas compared with cystadenomas, we only observed CN aberrations in the epithelium of cystadenofibromas and none in the epithelium of cystadenomas.
Pathologist reviews of the cases in this study failed to identify any distinguishing histologic features associated with detectable CN aberrations in the fibromatous components compared with those tumors without detectable fibromatous CN aberrations. One explanation may be that in fact the majority of these benign tumors do contain clonal fibromatous neoplasms that this molecular study has not detected due to the focus on CN analysis and mutations most commonly present in the epithelium of serous ovarian tumors. To date no highly recurrent mutated genes have been identified in fibromas that can be used to assess the true frequency of benign serous tumors that are fibromas.
Trisomy 12 has been previously identified as a characteristic CN aberration of the fibroma-thecoma group of sex cord-stromal tumors (37) (38) (39) (40) . Persons and colleagues ref. 41) found chromosome 12 gain in 40% of pure fibromas, very similar to the rate detected in the fibroblasts of this study. Although chromosome 12 gain has previously been identified in benign ovarian tumors these studies were done on whole tumors and therefore failed to identify the cell type of origin (40) . Our data clearly show for the first time that at least 40% of benign serous tumors are likely primary fibromas. It has been previously speculated that recurrent gain of chromosome 12 may be driven by a requirement for an extra copy of the KRAS oncogene for neoplasia in this milieu (42) . A correlation between trisomy 12 and increased KRAS expression has been shown in an adenosquamous carcinoma of the lung (43), however, this has not been shown experimentally in ovarian tumors. Other known oncogenes are located on chromosome 12, including CDK4, CCND2, MDM, WNT1, and ERBB3, along with a number of other genes of potential relevance in neoplasia. An intriguing finding of this study was the identification of one benign tumor and 3 borderline tumors with coexisting but unique CN aberrations in the epithelial and fibroblast components. Interestingly, loss of chromosome 22, the second most frequent CN aberration in fibromas detected in this study, was also detected by Qiu and colleagues (2005; ref. 29) in the fibroblast component of a high-grade endometrioid tumor. Although this was a single case in 25 cases analyzed, the presence of an underlying fibroma in another histologic subtype suggests this phenomenon may not be limited to serous tumors. This finding raises some interesting questions about the potential biological relationship between these tumor populations: are these biphasic tumors, collision tumors, or is it possible that the fibromatous component promotes tumorigenesis in the adjacent epithelium? The absence of shared point mutations and CN aberrations (within the limits of our assays) between the adjacent epithelial and fibroblast components would seem to rule out a mesenchymal-epithelial or epithelial-mesenchymal transition event underlying a biphasic tumor. The likelihood of these being collision tumors also seems highly unlikely given that the frequency of fibromas and genuine benign serous tumors is extremely low (44) . Speculatively, our data points to a unique ovarian tumorigenesis pathway whereby a pre-existing fibroma promotes proliferation and occasional transformation of the adjacent ovarian epithelium. Fibroblasts have long been recognized as an integral part of the tumor microenvironment influencing tumorigenesis, capable of both inhibitory and stimulatory influences on neoplasia in neighboring epithelia (45) . In model systems, artificially induced genetically altered fibroblasts have been previously shown to promote both initiation and progression of tumorigenesis in adjacent epithelia (46) (47) (48) . It has been proposed that in primary human cancers, adjacent fibroblasts (so called cancer associated fibroblasts) almost universally acquired clonal somatic genetic mutations in genes that promoted the progression of the adjacent cancer epithelium. Although that theory has subsequently been disproved (29) , our data for the first time suggests that in rare instances a genuine stromal tumor can promote tumorigenesis in adjacent epithelium. A possible mechanism for this to occur could be entrapment of epithelial cells within proliferating stroma that subsequently drives the formation of cystic masses. Under these circumstances we propose that growth factors secreted by the fibroma, or inhibitory factors no longer secreted by the fibroma, promote proliferation of the epithelium, which subsequently increases the likelihood of the epithelium acquiring or selecting for genetic alterations leading to neoplasia (Fig. 3) . The capacity for genetically altered fibroblasts to induce neoplasia in epithelial cells has been shown in a number of mouse models (49, 50) . This alternative pathway may exist independently of the classic pathways of low-grade serous tumors characterized by the presence of activating mutations in the oncogenes KRAS and BRAF in the epithelium and may even explain some high-grade serous and endometrioid tumors. This is the largest high-resolution study of benign serous tumors conducted to date and provides evidence that the majority of benign ovarian serous tumors are not epithelial neoplasms, but are in fact primary fibromas. This finding significantly deflates the prevalence of serous histologic subtype of ovarian neoplasms, of which benign tumors accounted for 60%. The findings of this study also provide preliminary evidence for a possible novel pathway of tumorigenesis dependent on a promoting primary fibroma.
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